Alto Neuroscience (NYSE:ANRO) Shares Down 6.9% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO) shares were down 6.9% during mid-day trading on Wednesday . The company traded as low as $19.78 and last traded at $19.6890. Approximately 101,812 shares traded hands during trading, a decline of 64% from the average daily volume of 286,108 shares. The stock had previously closed at $21.15.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wolfe Research initiated coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Bank of America initiated coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a report on Monday, March 16th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Trading Down 6.8%

The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a market cap of $691.73 million, a price-to-earnings ratio of -8.18 and a beta of 1.22. The company has a fifty day simple moving average of $22.78 and a 200-day simple moving average of $19.40.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, research analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several large investors have recently made changes to their positions in ANRO. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the first quarter worth $52,000. Torren Management LLC acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $62,000. Invesco Ltd. bought a new stake in Alto Neuroscience during the first quarter valued at $67,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after acquiring an additional 2,055 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.